InjuryBoard.com
By Jim Lewis
March 12, 2010
The multi-billion dollar drug company, Johnson & Johnson (J&J), has come under fire for allegedly violating the rules in their marketing of Risperdal, an antipsychotic drug. Back in 1999, the Food and Drug Administration (FDA) told J&J that their marketing materials for geriatric patients overstated Risperdals benefits and minimized risks, according to Bloomberg.com. In 2000, an internal business plan strategized a way to increase Risperdals market share by marketing the benefits for elderly dementia, an unapproved use.
This was described as one of the more egregious examples of marketing drugs to vulnerable patients by Jerry Avorn, who works at the Harvard Medical School. He went on to say, seeing such clear evidence in black and white of the details of a campaign like this is still pretty upsetting.
J&Js marketing of Risperdal could be illegal since current law states that drug companies cannot promote a drug for uses other than those approved by the FDA. At the time this marketing and business plan was crafted, Risperdal was only approved for psychotic disorders like schizophrenia, not for dementia.
Read entire article: http://virginiabeach.injuryboard.com/fda-and-prescription-drugs/johnson-johnson-internal-documents-reveal-unsavory-and-potentially-illegal-marketing-of-risperdal.aspx?googleid=279316
News Feed
Donate
